- Home
- JXG vs MRKR Comparison
JXG vs MRKR Comparison
Compare JXG & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JXG
- MRKR
- Stock Information
- Founded
- JXG N/A
- MRKR N/A
- Country
- JXG China
- MRKR United States
- Employees
- JXG N/A
- MRKR N/A
- Industry
- JXG
- MRKR Biotechnology: Pharmaceutical Preparations
- Sector
- JXG
- MRKR Health Care
- Exchange
- JXG Nasdaq
- MRKR Nasdaq
- Market Cap
- JXG 10.4M
- MRKR 11.6M
- IPO Year
- JXG N/A
- MRKR N/A
- Fundamental
- Price
- JXG $0.85
- MRKR $1.08
- Analyst Decision
- JXG
- MRKR Strong Buy
- Analyst Count
- JXG 0
- MRKR 3
- Target Price
- JXG N/A
- MRKR $13.17
- AVG Volume (30 Days)
- JXG 1.8M
- MRKR 313.3K
- Earning Date
- JXG 05-15-2025
- MRKR 11-13-2025
- Dividend Yield
- JXG N/A
- MRKR N/A
- EPS Growth
- JXG N/A
- MRKR N/A
- EPS
- JXG 0.86
- MRKR N/A
- Revenue
- JXG $49,840,288.00
- MRKR $5,388,071.00
- Revenue This Year
- JXG N/A
- MRKR N/A
- Revenue Next Year
- JXG N/A
- MRKR $9.35
- P/E Ratio
- JXG $1.03
- MRKR N/A
- Revenue Growth
- JXG 56.53
- MRKR 44.55
- 52 Week Low
- JXG $0.55
- MRKR $0.81
- 52 Week High
- JXG $7.72
- MRKR $5.95
- Technical
- Relative Strength Index (RSI)
- JXG 44.39
- MRKR 58.74
- Support Level
- JXG $0.71
- MRKR $0.85
- Resistance Level
- JXG $0.92
- MRKR $0.92
- Average True Range (ATR)
- JXG 0.10
- MRKR 0.06
- MACD
- JXG 0.01
- MRKR 0.02
- Stochastic Oscillator
- JXG 38.65
- MRKR 97.87
About JXG JX Luxventure Limited Common Stock
JX Luxventure Group Inc is engaged in the tourism sector and supplying related products, including technology solutions, to business partners in China, both online and offline. The company operates in three segments Tourism products, Technology, and Cross board merchandise The majority of the group revenue is generated from Tourism products.
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.